MedPath

Fluticasone furoate

Generic Name
Fluticasone furoate
Brand Names
Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst
Drug Type
Small Molecule
Chemical Formula
C27H29F3O6S
CAS Number
397864-44-7
Unique Ingredient Identifier
JS86977WNV
Background

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications. Fluticasone furoate was first approved in 2007.

Indication

Fluticasone furoate is indicated for once-daily maintenance (i.e. prophylactic) treatment of asthma in patients ≥5 years old. Fluticasone furoate is available in two combination medications - one in combination with vilanterol and one in combination with both vilanterol and umeclidinium- which are both indicated for the management of chronic obstructive pulmonary disease (COPD) and for the treatment of asthma in patients ≥18 years old for the vilanterol-umeclidinium-fluticasone product and ≥5 years old for the vilanterol-fluticasone product.

Fluticasone furoate is available over the counter as a nasal spray for the symptomatic treatment of hay fever and other upper respiratory allergies in patients ≥2 years old.

Associated Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergy, Seasonal Allergies
Clinical Trials
Related News

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: budesonide/formoterol
Drug: albuterol/salbutamol
Drug: Placebo to match budesonide/formoterol
Drug: Placebo to match FF/UMEC/VI
Drug: placebo to match tiotropium
Device: ELLIPTA
Device: MDI
Device: HandiHaler
First Posted Date
2018-03-27
Last Posted Date
2020-10-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
729
Registration Number
NCT03478683
Locations
🇳🇱

GSK Investigational Site, Zutphen, Netherlands

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Albuterol/salbutamol
Drug: Placebo to match tiotropium
Drug: Placebo to match FF/UMEC/VI
Device: ELLIPTA inhaler
Device: HANDIHALER
Device: MDI
First Posted Date
2018-03-22
Last Posted Date
2021-07-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
800
Registration Number
NCT03474081
Locations
🇷🇺

GSK Investigational Site, Voronezh, Russian Federation

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Inhaled Corticosteroid
Drug: COPD rescue medications
Drug: LABA
First Posted Date
2018-03-16
Last Posted Date
2020-09-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
3109
Registration Number
NCT03467425
Locations
🇬🇧

GSK Investigational Site, Warrington, United Kingdom

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Phase 3
Withdrawn
Conditions
Asthma
Interventions
Drug: FP/SAL
Drug: Albuterol/salbutamol
Device: ELLIPTA DPI
Device: Metered Dose Inhaler
Device: DISKUS DPI
Device: Connected Inhaler System
Device: RESPIMAT inhaler
First Posted Date
2017-12-19
Last Posted Date
2019-03-25
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT03376932

The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma

Phase 4
Withdrawn
Conditions
Asthma
Interventions
Drug: Salbutamol/Albuterol
First Posted Date
2017-12-06
Last Posted Date
2018-01-29
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT03363191

Effect of Vilanterol on Methacholine Challenge Results

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Placebos
First Posted Date
2017-10-19
Last Posted Date
2018-10-11
Lead Sponsor
University of Saskatchewan
Target Recruit Count
17
Registration Number
NCT03315000
Locations
🇨🇦

Asthma Research Lab - University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Arnuity® Ellipta® Drug Use Investigation

Completed
Conditions
Asthma
Interventions
First Posted Date
2017-06-12
Last Posted Date
2021-04-26
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
336
Registration Number
NCT03184480
Locations
🇯🇵

GSK Investigational Site, Nagasaki, Japan

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: UMEC
Drug: Albuterol/salbutamol
First Posted Date
2017-01-06
Last Posted Date
2020-10-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
425
Registration Number
NCT03012061
Locations
🇷🇺

GSK Investigational Site, Yaroslavl, Russian Federation

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

Phase 2
Active, not recruiting
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2016-12-23
Last Posted Date
2024-11-18
Lead Sponsor
University of Virginia
Target Recruit Count
95
Registration Number
NCT03002389
Locations
🇺🇸

Roselove NUNOO-ASARE, Keswick, Virginia, United States

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: Short Acting Beta 2 Agonist
First Posted Date
2016-09-07
Last Posted Date
2024-01-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
477
Registration Number
NCT02889809
Locations
🇿🇦

GSK Investigational Site, Cape Town, South Africa

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy